zolbetuximab
astellas
[]
astellas to present positive findings from phase 3 spotlight trial of zolbetuximab during 2023 asco gi cancers symposium $alpmy $tyo:4503 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice